HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. John's Wort "SuperFluids" Manufacturing Method Receives NIH Grant

This article was originally published in The Tan Sheet

Executive Summary

Aphios Corp. has been awarded a $1.1 mil., two-and-a-half-year "fast-track" Small Business Innovation Research grant from the NIH National Center for Complementary & Alternative Medicine. The subject of the grant is a manufacturing method using "SuperFluids," which the firm says allows better standardization of St. John's wort and other herbs.

You may also be interested in...



NIH ODS/NCCAM Fund Two Botanicals Research Centers

The NIH Office of Dietary Supplements and National Center for Complementary & Alternative Medicine have awarded $1.5 mil. annual funding for each of two dietary supplement research centers devoted to botanicals, the National Institutes of Health announced Oct. 6. The five-year awards are to the University of California at Los Angeles and the University of Illinois at Chicago.

NCCAM Advisory Council Approves Center's First Three Project Initiatives

The newly chartered National Advisory Council for Complementary & Alternative Medicine unanimously approved a project proposal entitled "Traditional, Indigenous Systems of Medicine" at its inaugural meeting Aug. 31-Sept. 1 in Rockville, Md.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS140515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel